Novo Nordisk's Stock Plummets by 20%. Ozempic Manufacturer Presents new CEO After Shocking cut of US Forecast
Reading Time: 2 minutes
Novo Nordisk's (i) stock suffered a heavy drop early Tuesday after the Danish manufacturer of weight loss products unexpectedly lowered its annual forecast for the US and appointed a new CEO. Surprising forecast reduction and its impact The pharmaceutical giant attributed its revised forecast to lower revenue expectations for its blockbuster drugs Wegovy and Ozempic in the US market. For 2025, the company now expects revenue growth between 8% and 14% in local currencies, down from previous expectations of 13-21%. Operating profit growth (EBIT)...
Read this article now with a free account.
Your benefits:
- Every month, you can read 5 articles from the premium section for free.
- Monthly 2 trial issues of the Trader newspaper for free.
- Create a personal watchlist with an overview of news about your stock.
